Chinese Academy of Sciences

Topharman Shanghai Co., Ltd.

Wigen Biomedicine Technology (shanghai) Co., Ltd.

Suzhou Vigonvita Life Sciences Co., Ltd.

East China University of Science and Technology

Topharman Shandong Co., Ltd.

Suzhou Suplead Life Sciences Co., Ltd.

Vigonvita Life Sciences Co., Ltd.

Fudan University

Yunnan University

Cisen Pharmaceutical Co., Ltd.

Nanjing Pailexing Pharmaceutical Technology Ltd.

Kingsound & Partner

Shanghai Institute of Materia Medica, Cas

Jiangsu Kanion Pharmaceutical Co., Ltd.

Hualiang Jiang

Kaixian Chen

Hong Tao Liu

Jiang Wang

Jian Li

Jia Tao Li

Jingshan Shen

Jingya Li

Zhen Wang

Yang He

Cheng Luo

Jianfeng Li

Yu Chen Zhou

Guanghui Tian

Jing Li

Yu Ying Wang

Zeng Li

Xin Xie

Ying Chen

Zheng Liu

Wei Zhu

Jun Wei Zhang

Hong Ding

Fei Zhao

Dong Zhang

Yuli Xie

Jing Lan Chen

Jian Wang

Jingkang Shen

Yubo Zhou

Xu Han

Honglin Li

Wei Tang

Lei Zhang

Hui Li

Bo Li

Hui Chen

Fei Ye

Lihong Hu

Lu Lu

Dan Li

Junhua Chen

Bing Zhang

Rongxia Zhang

Mingbo Su

Yuanyuan Zhang

Xiangrui Jiang

Bing Zhou

Weiming Chen

Xiaomin Luo

Jianhua Shen

Yaxi Yang

Yongjian Liu

Weiliang Zhu

Shengbin Zhou

Shuni Wang

Haifeng Sun

Liyan Yue

Wei Wan

Gang Qiao

Zhenjiang Zhao

Xiaojun Yang

Chunhui Wu

Shijie Chen

Xu Shen

Haji Akber Aisa

Zhiyi Yao

Jin Suo

Hao Shen

Panfeng Peng

Yi Jing Zhu

Guan Zhong Wang

Jing Zhao

Tao Sun

Yan Fu

Jianping Zuo

Yufang Xu

Peng Sun

Haiyan Zhang

Jinfeng Zhang

Yiping Wang

Chenglin Wu

Liumeng Yang

Yongtang Zheng

Fei Guo

Yu Gao

Fuqiang Zhu

Xican Tang

Bing Xiong

Fenghua Zhu

Zhijian Xu

Heng Li

Shibo Jiang

Liguang Lou

Lili Chen

Bin Dai

Weijuan Kan

Yi Zang

The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia (COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

Antiviral application of nucleoside analog or combination formulation containing nucleoside analog

Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.

Histone acetyltransferase (HAT) inhibitor and use thereof

A ketoamide compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically, the ketoamide compound shown in formula (A), a racemate, an enantiomer, or a diastereoisomer thereof, or any mixture of same, or a pharmaceutically active metabolite thereof, or a pharmaceutically acceptable salt, solvate, or prodrug thereof. The ketoamide compound can effectively inhibit coronavirus or Ebola virus, and thereby implement the prevention or treatment of diseases related to coronavirus or diseases related to Ebola virus.

Ketoamide compound and preparation method, pharmaceutical composition, and use thereof

Disclosed are a novel tetrahydroisoquinoline compound, a method for preparing intermediates thereof, a pharmaceutical composition thereof and the use thereof. The tetrahydroisoquinoline compound of the present invention has a good inhibitory effect on phosphodiesterase (PDE4), and can be used in the prevention, treatment or auxiliary treatment of multiple diseases associated with the activity or expression of phosphodiesterase, especially PDE4-associated immune and inflammatory diseases, such as psoriasis and arthritis.

Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof

The present invention relates to the fields of medicinal chemistry and pharmacotherapy, and specifically relates to the chemical compound of formula (I), and its racemate, R-isomer, S-isomer, pharmaceutically acceptable salt, and mixtures thereof, as well as its method for preparation, a pharmaceutical composition containing said chemical compound, and use as a lysine-specific demethylase 1 (LSD 1) inhibitor. The cyclopropylamine chemical compound to which the present invention relates may be used in the treatment of cancer.

Trans-indoline cyclopropylamine chemical compound, and method for preparation, pharmaceutical composition, and use thereof

Disclosed is use of a thieno[3,2-d]pyrimidin-4-one compound represented by general formula (I). Definition of each substituent is as stated in the description and claims, and the compound is used for preparing medicines for treating and/or preventing liver fibrosis and related diseases or preparing a DPP-4 inhibitor, or is used as a DPP-4 inhibitor.

Pharmaceutical use of thiophene [3,2-d] pyrimidine-4-ketone compound

The present invention provides a tetrahydroprotoberberine compound represented by the formula (I), enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof. The invention also provides a method for preparing the compound and the use thereof in the preparation of a medicament for preventing and/or treating central nervous system diseases.

Tetrahydroprotoberberine compound, preparation method therefor and uses thereof, and pharmaceutical composition

The present invention relates to use of an aminomethylenecyclohexane-1,3-dione compound, more particularly to use of a compound shown in the following formula (I) or a pharmaceutically acceptable salt thereof alone or in combination with other drug in preparing a drug for regulating or treating a disease related to autophagy, especially mammalian ATG8 homologous proteins. 

Use of aminomethylenecyclohexane-1,3-dione compound

Provided are use of a saponin compound of formula (I) or (II), or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament targeting PD-1. The medicament targeting PD-1 is one which treats a disease by inhibiting PD-1 from binding to a ligand thereof. The disease may be a tumor, an infection caused by a bacterium, a virus or a fungus, or an inflammatory disease. 

Saponin compound targeting PD-1 and application thereof

The present disclosure relates to a salt of phenyl pyrimidinone compound, a polymorph thereof and a pharmaceutical composition comprising the same and a use thereof, particularly relates to the hydrochlorate of phenyl pyrimidinone compound of following formula (I-A) and a pharmaceutically acceptable polymorph, solvate, hydrate, co-crystal, anhydrous substance, or amorphous form thereof, a pharmaceutical composition and a pharmaceutical unit dosage comprising the same, the preparing method and use thereof. 

Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof

The present invention relates to a bromodomain inhibitor. Provided are a compound represented by general formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, racemate, polymorph, solvate, or isotopically labeled compound (including deuterium substitution) thereof, a preparation method of the same, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof. 

Bromodomain inhibitor compound and use thereof

The present disclosure relates to a maleate salt of a benzothiophene compound, a crystalline form thereof, and a use thereof. Specifically, the present disclosure relates to a compound represented by formula (I-A), a crystalline form A thereof, a preparation method of a pharmaceutical composition including the same, and a use of the pharmaceutical composition in the preparation of drugs for preventing or treating diseases of the central nervous system. The compound represented by formula (I-A) and the crystalline form A thereof in the present disclosure have excellent physical and chemical properties, high oral bioavailability, excellent drugability, and are well-suited for pharmaceutical preparation, application, and preservation. 

Maleate salt of benzothiophene compound, crystalline form thereof, and use thereof

It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators. 

Compound used as autophagy regulator, and preparation method therefor and uses thereof

An antidepressant steroid compound and a preparation method and an application thereof; the structure of said compound is shown in formula (I), and the definition of each substituent is as described in the description and claims. Compound of the present invention may be used in the prevention, treatment, therapy or alleviation of a plurality of diseases and conditions such as depression. 

Antidepressant compound and preparation method and application thereof

Growing community of inventors

Shanghai, China

Hualiang Jiang